Matrix metalloproteinase-9 predicts pulmonary status declines in α1-antitrypsin deficiency

Respiratory Research

Volumn 12, Issue 1, 2011, Pages

  Omachi, Theodore A ^a,b   Eisner, Mark D ^c   Rames, Alexis ^d   Markovtsova, Lada ^e   Blanc, Paul D ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GENENTECH INC   (United States)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

^e Roche   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GELATINASE B;

ADULT; ARTICLE; CARBON MONOXIDE TRANSFER FACTOR; CARDIOPULMONARY EXERCISE TEST; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DISEASE EXACERBATION; EMPHYSEMA; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; INCREMENTAL SHUTTLE WALK TEST; LUNG DENSITY; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG TRANSFER FACTOR; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; OXYGEN SATURATION; PROTEIN BLOOD LEVEL; PROTEIN DEFICIENCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT PARAMETERS; TOTAL LUNG CAPACITY; ALPHA 1 ANTITRYPSIN DEFICIENCY; BLOOD; CROSS-SECTIONAL STUDY; DISEASE COURSE; ENZYMOLOGY; EXERCISE TOLERANCE; HOSPITALIZATION; LUNG; LUNG EMPHYSEMA; METABOLISM; MULTICENTER STUDY (TOPIC); PATHOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROGNOSIS; PROSPECTIVE STUDY; STATISTICAL MODEL; TIME; UPREGULATION; VITAL CAPACITY;

ALPHA 1-ANTITRYPSIN DEFICIENCY; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; EXERCISE TOLERANCE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LINEAR MODELS; LUNG; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TOTAL LUNG CAPACITY; UP-REGULATION; VITAL CAPACITY;

EID: 79953102248     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-12-35     Document Type: Article

References (52)

1. Punturieri A, Croxton TL, Weinmann GG, Kiley JP: Chronic obstructive pulmonary disease: a view from the NHLBI. Am J Respir Crit Care Med 2008, 178:441-443.
2. Wanner A: COPD: new lessons from alpha1-antitrypsin deficiency? Chest 2009, 135:1342-1344.
3. Barnes PJ, Shapiro SD, Pauwels RA: Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003, 22:672-688.
4. Vernooy JH, Lindeman JH, Jacobs JA, Hanemaaijer R, Wouters EF: Increased activity of matrix metalloproteinase-8 and matrix metalloproteinase-9 in induced sputum from patients with COPD. Chest 2004, 126:1802-1810.
5. Stockley RA: Biomarkers in COPD: time for a deep breath. Thorax 2007, 62:657-660.
6. Ioachimescu OC, Stoller JK: A review of alpha-1 antitrypsin deficiency. COPD 2005, 2:263-275.
7. Pinto-Plata V, Toso J, Lee K, Park D, Bilello J, Mullerova H, De Souza MM, Vessey R, Celli B: Profiling serum biomarkers in patients with COPD: associations with clinical parameters. Thorax 2007, 62:595-601.
8. Higashimoto Y, Iwata T, Okada M, Satoh H, Fukuda K, Tohda Y: Serum biomarkers as predictors of lung function decline in chronic obstructive pulmonary disease. Respir Med 2009, 103:1231-1238.
9. Brajer B, Batura-Gabryel H, Nowicka A, Kuznar-Kaminska B, Szczepanik A: Concentration of matrix metalloproteinase-9 in serum of patients with chronic obstructive pulmonary disease and a degree of airway obstruction and disease progression. J Physiol Pharmacol 2008,59(Suppl 6):145-152.
10. Vignola AM, Paganin F, Capieu L, Scichilone N, Bellia M, Maakel L, Bellia V, Godard P, Bousquet J, Chanez P: Airway remodelling assessed by sputum and high-resolution computed tomography in asthma and COPD. Eur Respir J 2004, 24:910-917.
11. Belvisi MG, Bottomley KM: The role of matrix metalloproteinases (MMPs) in the pathophysiology of chronic obstructive pulmonary disease (COPD): a therapeutic role for inhibitors of MMPs? Inflamm Res 2003, 52:95-100.
12. Muroski ME, Roycik MD, Newcomer RG, Van den Steen PE, Opdenakker G, Monroe HR, Sahab ZJ, Sang QX: Matrix metalloproteinase-9/gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis. Curr Pharm Biotechnol 2008, 9:34-46.
13. Segura-Valdez L, Pardo A, Gaxiola M, Uhal BD, Becerril C, Selman M: Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. Chest 2000, 117:684-694.
14. Atkinson JJ, Senior RM: Matrix metalloproteinase-9 in lung remodeling. Am J Respir Cell Mol Biol 2003, 28:12-24.
15. Collier IE, Wilhelm SM, Eisen AZ, Marmer BL, Grant GA, Seltzer JL, Kronberger A, He CS, Bauer EA, Goldberg GI: H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. J Biol Chem 1988, 263:6579-6587.
16. Senior RM, Griffin GL, Fliszar CJ, Shapiro SD, Goldberg GI, Welgus HG: Human 92- and 72-kilodalton type IV collagenases are elastases. J Biol Chem 1991, 266:7870-7875.
17. Liu Z, Zhou X, Shapiro SD, Shipley JM, Twining SS, Diaz LA, Senior RM, Werb Z: The serpin alpha1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. Cell 2000, 102:647-655.
18. Van den Steen PE, Proost P, Wuyts A, Van Damme J, Opdenakker G: Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood 2000, 96:2673-2681.
19. Stolk J, Cooper BG, Stoel B, Rames A, Rutman O, Soliman S, Stockley R: Retinoid treatment of Emphysema in Patients on the Alpha-1 International Registry. The REPAIR study: study design, methodology and quality control of study assessments. Ther Adv Respir Dis 2010, 4:319-332.
20. Gueders MM, Foidart JM, Noel A, Cataldo DD: Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in the respiratory tract: potential implications in asthma and other lung diseases. Eur J Pharmacol 2006, 533:133-144.
21. Mannello F: Serum or plasma samples? The "Cinderella" role of blood collection procedures: preanalytical methodological issues influence the release and activity of circulating matrix metalloproteinases and their tissue inhibitors, hampering diagnostic trueness and leading to misinterpretation. Arterioscler Thromb Vasc Biol 2008, 28:611-614.
22. European Respiratory Society Standardized lung function testing. Lung volumes and forced ventilatory flows.1993 update Eur Respir J 1993,6(suppl 16):5-40.
23. Cotes JE, Chinn DJ, Quanjer PH, Roca J, Yernault JC: Standardization of the measurement of transfer factor (diffusing capacity). Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993, 16:41-52.
24. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. American Journal of Respiratory and Critical Care Medicine 2001, 163:1256-1276.
25. Singh SJ, Morgan MD, Scott S, Walters D, Hardman AE: Development of a shuttle walking test of disability in patients with chronic airways obstruction. Thorax 1992, 47:1019-1024.
26. Parr DG, Dirksen A, Piitulainen E, Deng C, Wencker M, Stockley RA: Exploring the optimum approach to the use of CT densitometry in a randomised placebo-controlled study of augmentation therapy in alpha 1-antitrypsin deficiency. Respir Res 2009, 10:75.
27. Dirksen A, Friis M, Olesen KP, Skovgaard LT, Sorensen K: Progress of emphysema in severe alpha 1-antitrypsin deficiency as assessed by annual CT. Acta Radiol 1997, 38:826-832.
28. Dirksen A, Dijkman JH, Madsen F, Stoel B, Hutchison DC, Ulrik CS, Skovgaard LT, Kok-Jensen A, Rudolphus A, Seersholm N, Vrooman HA, Reiber JH, Hansen NC, Heckscher T, Viskum K, Stolk J: A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999, 160:1468-1472.
29. Dowson LJ, Guest PJ, Stockley RA: Longitudinal changes in physiological, radiological, and health status measurements in alpha(1)-antitrypsin deficiency and factors associated with decline. Am J Respir Crit Care Med 2001, 164:1805-1809.
30. Parr DG, Stoel BC, Stolk J, Stockley RA: Validation of computed tomographic lung densitometry for monitoring emphysema in alpha1-antitrypsin deficiency. Thorax 2006, 61:485-490.
31. Newell JD Jr, Hogg JC, Snider GL: Report of a workshop: quantitative computed tomography scanning in longitudinal studies of emphysema. Eur Respir J 2004, 23:769-775.
32. Spouge D, Mayo JR, Cardoso W, Muller NL: Panacinar emphysema: CT and pathologic findings. J Comput Assist Tomogr 1993, 17:710-713.
33. Gevenois PA, De Vuyst P, de Maertelaer V, Zanen J, Jacobovitz D, Cosio MG, Yernault JC: Comparison of computed density and microscopic morphometry in pulmonary emphysema. Am J Respir Crit Care Med 1996, 154:187-192.
34. Dowson LJ, Newall C, Guest PJ, Hill SL, Stockley RA: Exercise capacity predicts health status in alpha(1)-antitrypsin deficiency. Am J Respir Crit Care Med 2001, 163:936-941.
35. Knudson RJ, Standen JR, Kaltenborn WT, Knudson DE, Rehm K, Habib MP, Newell JD: Expiratory computed tomography for assessment of suspected pulmonary emphysema. Chest 1991, 99:1357-1366.
36. Dawkins PA, Dowson LJ, Guest PJ, Stockley RA: Predictors of mortality in alpha1-antitrypsin deficiency. Thorax 2003, 58:1020-1026.
37. Stoel BC, Putter H, Bakker ME, Dirksen A, Stockley RA, Piitulainen E, Russi EW, Parr D, Shaker SB, Reiber JH, Stolk J: Volume correction in computed tomography densitometry for follow-up studies on pulmonary emphysema. Proc Am Thorac Soc 2008, 5:919-924.
38. Burge S, Wedzicha JA: COPD exacerbations: definitions and classifications. Eur Respir J Suppl 2003, 41:46s-53s.
39. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356:775-789.
40. Rodriguez-Roisin R: Toward a consensus definition for COPD exacerbations. Chest 2000, 117:398S-401S.
41. Feise RJ: Do multiple outcome measures require p-value adjustment? BMC Med Res Methodol 2002, 2:8.
42. Hanley JA, Negassa A, Edwardes MD, Forrester JE: Statistical analysis of correlated data using generalized estimating equations: an orientation. Am J Epidemiol 2003, 157:364-375.
43. Vittinghoff E, Glidden DV, Shiboski SC, McCulloch CE: Regression Methods in Biostatistics: Linear, Logistic, Survival, and Repeated Measures Models. New York: Springer Science & Business Media, Inc; 2005.
44. Burton P, Gurrin L, Sly P: Extending the simple linear regression model to account for correlated responses: an introduction to generalized estimating equations and multi-level mixed modelling. Stat Med 1998, 17:1261-1291.
45. Horton NJ, Lipsitz SR: Review of software to fit generalized estimating equation regression models. Am Stat 1999, 53:160-169.
46. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG: C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175:250-255.
47. Man SF, Connett JE, Anthonisen NR, Wise RA, Tashkin DP, Sin DD: C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006, 61:849-853.
48. Vignola AM, Riccobono L, Mirabella A, Profita M, Chanez P, Bellia V, Mautino G, D'Accardi P, Bousquet J, Bonsignore G: Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. Am J Respir Crit Care Med 1998, 158:1945-1950.
49. Cerveri I, Pellegrino R, Dore R, Corsico A, Fulgoni P, van de Woestijne KP, Brusasco V: Mechanisms for isolated volume response to a bronchodilator in patients with COPD. J Appl Physiol 2000, 88:1989-1995.
50. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group Am J Respir Crit Care Med 1998, 158:49-59.
51. de Torres JP, Pinto-Plata V, Casanova C, Mullerova H, Cordoba-Lanus E, Muros de Fuentes M, Aguirre-Jaime A, Celli BR: C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest 2008, 133:1336-1343.
52. Mao JT, Tashkin DP, Belloni PN, Baileyhealy I, Baratelli F, Roth MD: All-trans retinoic acid modulates the balance of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in patients with emphysema. Chest 2003, 124:1724-1732.